Mass.-based insulin-pump maker Insulet acquired assets related to Bigfoot Biomedical's pump-based automated insulin delivery (AID) technologies for $25 million.
Insulet and Bigfoot offer two distinct forms of diabetes-management care: Insulet's Omnipod system that delivers insulin via a wearable, tubeless pump dubbed the Pod; and a remote controller called the Personal Diabetes Manager (PDM)....
This morning, Bigfoot Biomedical announced it has received FDA 510(k) clearance for its Bigfoot Unity Diabetes Management System.
The system was cleared for use among individuals 12 years old and up with Type 1 or Type 2 diabetes who use multiple-dose injection therapy.
Included in the Bigfoot Unity System are two smartpen caps for both rapid- and long-acting insulin, a connected mobile app, an...
This morning Bigfoot Biomedical, a diabetes startup focused on automating insulin delivery through a connected insulin pen, picked up an extra $10 million Series C funding, closing the round at $55 million. Pharma giant Abbott led the round with participation from Quadrant Capital Advisors Senvest Capital, Janus Henderson, Cormorant Asset Management and other funders.
When the first $45 million...
Bigfoot Biomedical, a diabetes startup looking to automate insulin delivery via a connected insulin pen, has kicked off its Series C round with an initial tranche of $45 million. The raise is headed once again by Abbott, with prior backers Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management pitching in once again.
Alongside the news of its raise, Bigfoot...
A diabetes startup that uses artificial intelligence, Bigfoot Biomedical, has just announced that it scored a total of $55 million in Series B equity financing with new investments from Abbott and other existing funders.
This funding is the culmination of earlier round funding that the company has been raising since late last year, including $37 million that it raised in December and an...
Milpitas, California-based diabetes management device maker Bigfoot Biomedical has raised $37 million in Series B funding in a round co-led by funds from Janus Henderson Investors and Quadrant Capital Advisors. Additional participants included Cormorant Asset Management, Senvest Capital Inc., Senvest Management LLC, Visionnaire Ventures, JDRF T1D Fund, and T1D Exchange.
Bigfoot previously...
Oscar Health is working with Humana to offer commercial health insurance to small businesses in a nine-county Nashville, Tenn. area. Tech-saavy insurance startup Oscar is teaming up with incumbent Humana at a time when it’s just begun to expand from the individual market into working with employers through its Oscar for Business unit. Humana will provide licenses to operate in Nashville as well...
Abbott and Bigfoot Biomedical have entered into an agreement to develop and commercialize diabetes management systems, integrating Abbott's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions.
Under the agreement, Abbott will supply glucose measurement sensors for all of Bigfoot's insulin delivery systems in the U.S. as the exclusive sensors for those systems...
Milpitas, California-based Bigfoot Biomedical, a diabetes management company working on their first product, announced an investment from the Juvenile Diabetes Research Foundation (JDRF)’s newly launched venture fund, T1D, focused on early stage companies working on type 1 diabetes. The terms of the investment were not disclosed, but Bigfoot previously raised $35.5 million.
The funding will be...
Milpitas, California-based diabetes management company Bigfoot Biomedical has raised $35.5 million in Series A funding in a round with participation from Cormorant Asset Management, Senvest Capital and Visionnaire Ventures. The funding will be used to further develop the company’s connected, automated insulin delivery service.
Bigfoot bills itself as “drawing a circle around everything that it...
